P
128.32
5.88 (4.80%)
| Penutupan Terdahulu | 122.44 |
| Buka | 124.33 |
| Jumlah Dagangan | 134,942 |
| Purata Dagangan (3B) | 314,640 |
| Modal Pasaran | 1,836,728,832 |
| Harga / Buku (P/B) | 62.75 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| EPS Cair (TTM) | -2.08 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.67% |
| Nisbah Semasa (MRQ) | 8.84 |
| Aliran Tunai Operasi (OCF TTM) | -16.51 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.43 M |
| Pulangan Atas Aset (ROA TTM) | -18.40% |
| Pulangan Atas Ekuiti (ROE TTM) | -89.30% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Palvella Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.9
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.88 |
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 22.87% |
| % Dimiliki oleh Institusi | 47.68% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Summit Partners Public Asset Management, Llc | 31 Dec 2025 | 389,420 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 255.00 (HC Wainwright & Co., 98.72%) | Beli |
| Median | 232.50 (81.19%) | |
| Rendah | 210.00 (Chardan Capital, 63.65%) | Beli |
| Purata | 232.50 (81.19%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 124.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 25 Feb 2026 | 215.00 (67.55%) | Beli | 128.60 |
| Mizuho | 25 Feb 2026 | 250.00 (94.83%) | Beli | 128.60 |
| Chardan Capital | 24 Feb 2026 | 210.00 (63.65%) | Beli | 120.41 |
| HC Wainwright & Co. | 24 Feb 2026 | 255.00 (98.72%) | Beli | 120.41 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |